Pfizer calls a halt to Phase III study of Sutent in prostate cancer

28 September 2010

Pfizer has discontinued a Phase III clinical trial of its Sutent (sunitinib malate) product in advanced castration-resistant prostate cancer after it failed to improve survival.

The news comes hard on the heels of disappointing results with AstraZeneca's drug zibotentan in the same indication and will be a real blow to prostate cancer sufferers who desperately need more effective therapies for the disease.

In a statement, Pfizer said an interim analysis of the SUN 1120 study showed that the addition of Sutent to chemotherapy with prednisone was not likely to show an improvement to overall survival in the patients, whose cancer had advanced despite prior treatment with a docetaxel-based regimen.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK